Palantir’s chief executive Alex Karp has signaled that he may offload 675,000 shares worth roughly $99.7 million, a filing that landed just as the stock was absorbing a 6.5% slide amid a broad retreat from artificial-intelligence names. The disclosure, lodged yesterday, is a heads-up rather than a receipt: it outlines possible transactions without confirming that a single share has changed hands.
What the Paperwork Actually Says
The notice comes via a Form 144, which merely flags intent. Only a Form 4 confirms executed trades, so the headline figure should not be read as a completed sale β and the final tally may come in smaller than advertised.
Breaking down the total, 90,000 shares stem from equity-based compensation in the form of RSUs, governed by a 10b5-1 trading plan put in place on March 12. Because that arrangement predates the recent market turbulence, the timing of the filing does not by itself show Karp reacting to the selloff. The remaining 585,000 shares are restricted stock, equal to 60% of the tranche due for release, meaning the actual disposal could fall short of the announced amount.
A Bruising Session for AI Stocks
The backdrop was hardly friendly. Palantir shed 6.5% yesterday to close at β¬130.94 as investors reassessed valuations and spending across the AI sector, according to AP, with the selling pressure hitting AI-linked companies across the board. That downdraft, rather than Karp’s filing, explains the day’s losses β the two events simply coincided.
The disconnect between the share price and the business has grown stark. Palantir reported third-quarter 2026 revenue of $2.313 billion, up 96% year on year. Even after the company raised its revenue guidance, media reports said lofty valuation expectations kept weighing on the stock. Strong numbers, in other words, offered no shelter.
The valuation has lately been pegged at 204 times trailing earnings. Against that multiple, a large proposed sale by the chief executive draws outsized scrutiny.
Should investors sell immediately? Or is it worth buying Palantir?
Europe Weighs Its Options
Meanwhile, the company’s overseas footing is being tested. Reuters reported that European defense ministries are hunting for alternatives to US technology, Palantir’s military software among the targets. In a report dated November 16, the agency said Palantir was not among the options shortlisted in Germany. The Netherlands, for its part, aims to deploy a European alternative within two years, with the push driven by a desire to curb reliance on American suppliers.
In Britain, the government has announced a fresh tender for the NHS Federated Data Platform. Palantir remains the incumbent supplier through 2029, with the current contract running until March 2029.
On the analyst front, Phillip Securities raised its price target on November 16 to $248 from $215 while keeping its buy rating β a higher mark paired with an unchanged recommendation.
For investors, the takeaway is to keep three threads apart: the operational momentum, the valuation, and insider transactions that have actually been executed. Karp’s filing describes a possible sale; whether it materializes, and on what scale, will only become clear from the follow-up execution reports.
Ad
Palantir Stock: Buy or Sell?! New Palantir Analysis from November 21 delivers the answer:
The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 21.
Palantir: Buy or sell? Read more here...
